News Conference News ESC 2021 Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention Michael O'Riordan August 31, 2021
News Conference News ESC 2021 IAMI: Influenza Vaccine Beneficial for Post-MI Patients Michael O'Riordan August 30, 2021
News Daily News Smoking, Drinking, and Drugs—All Signs Point to Earlier ASCVD Michael O'Riordan February 19, 2021
News Daily News Fewer Diagnostic Tests, Higher CV Mortality During COVID-19 Pandemic Michael O'Riordan January 12, 2021
News Conference News ESC 2020 ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA Michael O'Riordan September 01, 2020
News Daily News Higher Risk of HF After ACS for Women Previously on Beta-blockers Michael O'Riordan July 16, 2020
News Conference News EuroPCR 2020 No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms Michael O'Riordan June 26, 2020
News Conference News ACC 2020 ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up Shelley Wood March 30, 2020
News Daily News Type 2 MI Linked to More CV Deaths, Even in Younger Patients Shelley Wood March 04, 2020
News Daily News Recurrent Events Common Among Young Patients With CAD Michael O'Riordan October 11, 2019
News Conference News SCCT 2019 Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology Yael L. Maxwell July 15, 2019
News Daily News Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention Michael O'Riordan May 20, 2019
News Conference News EHRA 2019 High-Dose Nifedipine Tied to Higher Cardiac Arrest Risk Todd Neale March 18, 2019
News Daily News Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony Michael O'Riordan March 15, 2019
News Daily News Lower Statin Adherence Linked to Higher Mortality Risk, Even Among Patients With Established ASCVD Lucy Hicks February 15, 2019
News Daily News Flu Tied to Worse Outcomes in Patients Hospitalized With Heart Failure Todd Neale January 03, 2019
News Daily News Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention Michael O'Riordan December 10, 2018
News Conference News AHA 2018 Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study Michael O'Riordan November 15, 2018
News Daily News ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom Michael O'Riordan November 07, 2018